Medifast, Inc.
MED Details
Medifast, Inc. (NYSE: MED) is a global health and wellness company that develops and distributes nutritional products and strategies to help people lose weight, maintain weight loss, and live a healthy lifestyle. Its coaches teach the skill of establishing holistic, healthy habits through its unique "Habits of Health" Transformational System in the United States and Asia Pacific (Hong Kong and Singapore) through its community, OPTAVIA.
Latest News:
- Quarterly Dividend: On March 17, 2022, the company announced a quarterly dividend of USD 1.64 per common share, payable on May 09, 2022, to shareholders of record on March 29, 2022.
FY21 Results:
- Surge in Revenue: In FY21, the company's total revenue amounted to USD 1.53 billion, representing a 63.25% increase year-over-year from USD 934.84 million in FY20.
- Revenue per Active Earning OPTAVIA Coach: In Q4FY21, MED reported that the average revenue per active earning OPTAVIA Coach was USD 6,321 vs. USD 5,932 for FY20, driven by an increase in the number of clients managed by each coach, along with an increase in average client spend.
- Sharp Uptick in Net Income: The company's net income increased to USD 164.03 million in FY21 from USD 102.86 million in FY20, representing diluted EPS of USD 13.89 in FY21.
- Cash and Debt Position: The company had USD 109.54 million in cash and cash equivalents as of December 31, 2021, and no outstanding debt.
Key Risk:
- Dependence on Third-Party Manufacturers: Third-party manufacturers supply most of MED's food and other products. If these manufacturers fail to provide products with inadequate quantity/quality on schedule and at acceptable costs, their financials and reputations may suffer.
- Competition Risk: In the weight management sector, several significant and emerging players compete directly with MED, supplying various products such as digital tools, app-based health and wellness monitoring systems, and so on. If demand for these rivals' products rises, it could harm MED's operating results.
Outlook:
- FY22 Guidance: In FY22, the company anticipates revenue of USD 1.72–1.79 billion and EPS of USD 14.50–16.00.
Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
MED's stock price has fallen 37.56% in the past nine months and is currently leaning towards the lower end of its 52-week range of USD 161.44 to USD 336.99. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 150.09.
Considering the correction in the stock price, robust dividend yield, positive outlook, associated risks, and current valuation. We recommend a "Hold" rating on the stock at the current price of USD 174.485, down 2.17% as of May 02, 2022, at 09:22 AM PDT.
Three-Year Technical Price Chart (as on May 02, 2022, at 09:22 AM PDT). Source: REFINITIV, Analysis by Kalkine Group
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: All forecasted figures and industry information have been taken from REFINITIV.
Note 3: The report publishing date is as per the Pacific Time Zone.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.